Mario Balsa, Medical Oncologist at Hospital Clínic de Barcelona, shared on X:
“Bispecifics and beyond in melanoma.
Melanoma may be short on surface targets, but not on ideas.
- GD2 emerges as an attractive candidate for GD2×CD3 BiTEs
- Still largely preclinical
- And with tebentafusp, the TME matters: fewer M2 macrophages relative to CD3+ T cells -> longer survival.”
You can also read:
INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma
